Sponsor

China Immunotech (Beijing) Biotechnology Co., Ltd.

Clinical research sponsor

Published trials6
Recruiting shown3
Roles2
SourceClinicalTrials.gov

Clinical trials

6 shown
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesNCT07236762 · lead sponsor · 2025-11-24
RECRUITING
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune DiseasesNCT07236801 · lead sponsor · 2025-11-13
RECRUITING
A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesNCT06978647 · lead sponsor · 2025-05-19
RECRUITING
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune DiseaseNCT06379646 · lead sponsor · 2024-04-24
UNKNOWN
A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.NCT07523100 · collaborator · 2026-04-07
NOT_YET_RECRUITING
YTS109 in Pediatric Relapsed/Refractory Autoimmune DiseasesNCT07439029 · collaborator · 2026-03-01
NOT_YET_RECRUITING

Sponsor roles

lead sponsor4
collaborator2

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.